Adverum Biotechnologies, Inc. (ADVM)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Adverum Biotechnologies, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Adverum Biotechnologies, Inc. (ADVM) has returned 0.00% so far this year and -0.23% over the past 12 months. Over the last ten years, ADVM has returned -21.95% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.

Based on dividend-adjusted daily data since Jan 4, 2016, ADVM's average daily return is +0.02%, while the average monthly return is +0.62%. At this rate, your investment would double in approximately 9.3 years.

Historically, 45% of months were positive and 55% were negative. The best month was Jan 2018 with a return of +108.6%, while the worst month was Apr 2021 at -60.5%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 5 months.

On a daily basis, ADVM closed higher 46% of trading days. The best single day was May 5, 2020 with a return of +38.4%, while the worst single day was Apr 29, 2021 at -62.3%.

Adverum Biotechnologies, Inc. has an annualized alpha of -10.06%, beta of 1.19, and R² of 0.07 versus S&P 500 Index. Calculated based on daily prices since January 05, 2016.

• This stock participated in 194.70% of S&P 500 Index downside but only 40.32% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.07 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

ADVM ranks 42 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The table below present risk-adjusted performance metrics for Adverum Biotechnologies, Inc. (ADVM) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Adverum Biotechnologies, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Adverum Biotechnologies, Inc. was 99.20%, occurring on May 15, 2025. The portfolio has not yet recovered.

The current Adverum Biotechnologies, Inc. drawdown is 98.30%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Adverum Biotechnologies, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Adverum Biotechnologies, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.